JP2004504388A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004504388A5 JP2004504388A5 JP2002514115A JP2002514115A JP2004504388A5 JP 2004504388 A5 JP2004504388 A5 JP 2004504388A5 JP 2002514115 A JP2002514115 A JP 2002514115A JP 2002514115 A JP2002514115 A JP 2002514115A JP 2004504388 A5 JP2004504388 A5 JP 2004504388A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- phenyl
- dichloro
- amide according
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001408 amides Chemical class 0.000 claims 19
- 229910052760 oxygen Inorganic materials 0.000 claims 15
- 229910052717 sulfur Chemical group 0.000 claims 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 11
- 239000001301 oxygen Substances 0.000 claims 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000011593 sulfur Chemical group 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 150000001721 carbon Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 229910002091 carbon monoxide Inorganic materials 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 229910052757 nitrogen Chemical group 0.000 claims 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003568 thioethers Chemical class 0.000 claims 2
- XTDQXQIDBRVLFJ-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-2-(oxan-4-yloxy)-n-(1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1SC=CN=1)OC1CCOCC1 XTDQXQIDBRVLFJ-UHFFFAOYSA-N 0.000 claims 1
- MIEVEFJYIVXWLB-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-n-(methylcarbamoyl)-2-(oxan-4-yloxy)acetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCOCC1 MIEVEFJYIVXWLB-UHFFFAOYSA-N 0.000 claims 1
- LNNBWXQTZQJUMS-UHFFFAOYSA-N 2-(3-chloro-4-methylsulfonylphenyl)-2-cyclohex-2-en-1-yloxy-n-(4,5-dihydro-1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SCCN=1)OC1C=CCCC1 LNNBWXQTZQJUMS-UHFFFAOYSA-N 0.000 claims 1
- AKTVVVWFNHFFQE-UHFFFAOYSA-N 2-(3-chloro-4-methylsulfonylphenyl)-2-cyclohex-2-en-1-yloxy-n-(methylcarbamoyl)acetamide Chemical compound C=1C=C(S(C)(=O)=O)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCCC=C1 AKTVVVWFNHFFQE-UHFFFAOYSA-N 0.000 claims 1
- CNNNBBYSLRJXCB-UHFFFAOYSA-N 2-(3-chloro-4-methylsulfonylphenyl)-2-cyclopentyloxy-n-(1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(S(=O)(=O)C)=CC=C1C(C(=O)NC=1SC=CN=1)OC1CCCC1 CNNNBBYSLRJXCB-UHFFFAOYSA-N 0.000 claims 1
- GDLVELQZXTUWHH-UHFFFAOYSA-N 2-(3-chloro-4-methylsulfonylphenyl)-2-cyclopentyloxy-n-(methylcarbamoyl)acetamide Chemical compound C=1C=C(S(C)(=O)=O)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCCC1 GDLVELQZXTUWHH-UHFFFAOYSA-N 0.000 claims 1
- OKVVHUTYWMKAMT-UHFFFAOYSA-N 2-cyclohex-2-en-1-yloxy-2-(3,4-dichlorophenyl)-n-(1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1SC=CN=1)OC1C=CCCC1 OKVVHUTYWMKAMT-UHFFFAOYSA-N 0.000 claims 1
- GBRFVNIVLOASHK-UHFFFAOYSA-N 2-cyclohex-2-en-1-yloxy-2-(3,4-dichlorophenyl)-n-(methylcarbamoyl)acetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCCC=C1 GBRFVNIVLOASHK-UHFFFAOYSA-N 0.000 claims 1
- MMNSTTDMQWXPIG-UHFFFAOYSA-N 2-cyclohexyloxy-2-(3,4-dichlorophenyl)-n-(1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1SC=CN=1)OC1CCCCC1 MMNSTTDMQWXPIG-UHFFFAOYSA-N 0.000 claims 1
- PZDFZWWTLUQGLV-UHFFFAOYSA-N 2-cyclohexyloxy-2-(3,4-dichlorophenyl)-n-(methylcarbamoyl)acetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCCCC1 PZDFZWWTLUQGLV-UHFFFAOYSA-N 0.000 claims 1
- POASZSTXBAHPDO-UHFFFAOYSA-N 2-cyclopentyloxy-2-(3,4-dichlorophenyl)-n-(1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1SC=CN=1)OC1CCCC1 POASZSTXBAHPDO-UHFFFAOYSA-N 0.000 claims 1
- AQFOGDIAJYVUPT-UHFFFAOYSA-N 2-cyclopentyloxy-2-(3,4-dichlorophenyl)-n-(methylcarbamoyl)acetamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C(=O)NC(=O)NC)OC1CCCC1 AQFOGDIAJYVUPT-UHFFFAOYSA-N 0.000 claims 1
- VDMFSJBFMOBHGB-UHFFFAOYSA-N 2-cyclopentyloxy-2-(3,4-dichlorophenyl)-n-pyridin-2-ylacetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)NC=1N=CC=CC=1)OC1CCCC1 VDMFSJBFMOBHGB-UHFFFAOYSA-N 0.000 claims 1
- WAUWSYSGLFXHRD-UHFFFAOYSA-N 2-cyclopentylsulfonyl-2-(3,4-dichlorophenyl)-n-(1,3-thiazol-2-yl)acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(S(=O)(=O)C1CCCC1)C(=O)NC1=NC=CS1 WAUWSYSGLFXHRD-UHFFFAOYSA-N 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- UMLQXVZOFOAQFB-UHFFFAOYSA-N 3-cyclopentyl-2-(3,4-dichlorophenyl)-3-oxo-n-(1,3-thiazol-2-yl)propanamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C(=O)C1CCCC1)C(=O)NC1=NC=CS1 UMLQXVZOFOAQFB-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- -1 alkali metal alkoxide Chemical class 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000005595 deprotonation Effects 0.000 claims 1
- 238000010537 deprotonation reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21987200P | 2000-07-20 | 2000-07-20 | |
| PCT/EP2001/007994 WO2002008209A1 (en) | 2000-07-20 | 2001-07-11 | Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004504388A JP2004504388A (ja) | 2004-02-12 |
| JP2004504388A5 true JP2004504388A5 (enExample) | 2005-02-17 |
| JP4138478B2 JP4138478B2 (ja) | 2008-08-27 |
Family
ID=22821104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002514115A Expired - Fee Related JP4138478B2 (ja) | 2000-07-20 | 2001-07-11 | アルファ−アシル及びアルファ−ヘテロ原子置換ベンゼンアセトアミドのグルコキナーゼアクチベーター |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US6486184B2 (enExample) |
| EP (1) | EP1305301B1 (enExample) |
| JP (1) | JP4138478B2 (enExample) |
| KR (1) | KR100556323B1 (enExample) |
| CN (1) | CN1184214C (enExample) |
| AR (1) | AR032626A1 (enExample) |
| AT (1) | ATE297907T1 (enExample) |
| AU (2) | AU8760001A (enExample) |
| BR (1) | BR0112658A (enExample) |
| CA (1) | CA2416229C (enExample) |
| DE (1) | DE60111534T2 (enExample) |
| DK (1) | DK1305301T3 (enExample) |
| ES (1) | ES2243547T3 (enExample) |
| GT (1) | GT200100146A (enExample) |
| MX (1) | MXPA03000365A (enExample) |
| PA (1) | PA8522701A1 (enExample) |
| PE (1) | PE20020335A1 (enExample) |
| PT (1) | PT1305301E (enExample) |
| UY (1) | UY26850A1 (enExample) |
| WO (1) | WO2002008209A1 (enExample) |
| ZA (1) | ZA200300173B (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| EP1336607A1 (en) * | 2002-02-19 | 2003-08-20 | Novo Nordisk A/S | Amide derivatives as glucokinase activators |
| IL162620A0 (en) | 2001-12-21 | 2005-11-20 | Novo Nordisk As | Amide derivatives as gk activators |
| AU2003232204B8 (en) * | 2002-04-26 | 2009-07-30 | F. Hoffmann-La Roche Ag | Substituted phenylacetamides and their use as glucokinase activators |
| KR101116627B1 (ko) | 2002-06-27 | 2012-10-09 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
| KR101124245B1 (ko) | 2002-06-27 | 2012-07-02 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
| NZ539013A (en) | 2002-10-03 | 2007-05-31 | Novartis Ag | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| US7132425B2 (en) | 2002-12-12 | 2006-11-07 | Hoffmann-La Roche Inc. | 5-substituted-six-membered heteroaromatic glucokinase activators |
| AU2003294376A1 (en) * | 2003-01-06 | 2004-08-10 | Eli Lilly And Company | Heteroaryl compounds |
| PL378117A1 (pl) * | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| WO2005030797A2 (en) | 2003-09-30 | 2005-04-07 | Novo Nordisk A/S | Melanocortin receptor agonists |
| EP2298337B1 (en) | 2003-12-09 | 2017-02-22 | Novo Nordisk A/S | Regulation of food preference using GLP-1 agonists |
| MXPA06007667A (es) | 2004-01-06 | 2006-09-01 | Novo Nordisk As | Heteroaril-ureas y su uso como activadores de glucocinasa. |
| KR100830007B1 (ko) | 2004-04-02 | 2008-05-15 | 노파르티스 아게 | 2형 당뇨병 치료에 유용한 글루코키나제 활성화제로서의술폰아미드-티아졸피리딘 유도체 |
| KR20070006816A (ko) | 2004-04-02 | 2007-01-11 | 노파르티스 아게 | 티아졸로피리딘 유도체, 이를 함유하는 제약 조성물 및글루코키나제 매개형 증상의 치료 방법 |
| EA012204B1 (ru) * | 2004-04-21 | 2009-08-28 | Прозидион Лимитед | Три(цикло)замещённые амидные соединения |
| US8410047B2 (en) | 2004-06-11 | 2013-04-02 | Novo Nordisk A/S | Counteracting drug-induced obesity using GLP-1 agonists |
| CN101035767A (zh) * | 2004-08-12 | 2007-09-12 | 普洛希典有限公司 | 被取代的苯乙酰胺及其作为葡糖激酶激活剂的用途 |
| GB0418046D0 (en) * | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Eantioselective process |
| MX2008000294A (es) * | 2005-07-08 | 2008-04-04 | Novo Nordisk As | Activadores de dicicloalquil urea glucocinasa. |
| ES2382815T3 (es) | 2005-07-08 | 2012-06-13 | Novo Nordisk A/S | Dicicloalquilcarbamoil ureas como activadores de glucoquinasa |
| NZ564608A (en) | 2005-07-09 | 2009-09-25 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| ES2422383T3 (es) | 2005-07-14 | 2013-09-11 | Novo Nordisk As | Activadores de urea glucoquinasa |
| US8106090B2 (en) | 2005-07-20 | 2012-01-31 | Eli Lilly And Company | 1-amino linked compounds |
| EP1921074A1 (en) | 2005-08-31 | 2008-05-14 | Astellas Pharma Inc. | Thiazole derivative |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| AU2006299091A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| GT200600428A (es) | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| BRPI0618062A2 (pt) * | 2005-11-03 | 2011-08-16 | Prosidion Ltd | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto |
| US7863329B2 (en) | 2005-11-17 | 2011-01-04 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
| US20070197532A1 (en) * | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
| JP5302012B2 (ja) | 2006-03-08 | 2013-10-02 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤 |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| ATE522518T1 (de) | 2006-05-31 | 2011-09-15 | Takeda San Diego Inc | Indazol- und isoindolderivate als glucokinaseaktivierende stoffe |
| US7888504B2 (en) | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| WO2008059025A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes |
| US7902248B2 (en) | 2006-12-14 | 2011-03-08 | Hoffmann-La Roche Inc. | Oxime glucokinase activators |
| WO2008079787A2 (en) | 2006-12-20 | 2008-07-03 | Takeda San Diego, Inc. | Glucokinase activators |
| TW200831081A (en) * | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| WO2008084043A1 (en) | 2007-01-09 | 2008-07-17 | Novo Nordisk A/S | Urea glucokinase activators |
| WO2008084044A1 (en) | 2007-01-11 | 2008-07-17 | Novo Nordisk A/S | Urea glucokinase activators |
| JP5491871B2 (ja) | 2007-02-28 | 2014-05-14 | アドビナス セラピュティックス プライベート リミテッド | グルコキナーゼ活性化因子としての２，２，２−三置換アセトアミド誘導体、その方法及び薬学的応用 |
| KR20090121376A (ko) * | 2007-03-07 | 2009-11-25 | 교린 세이야꾸 가부시키 가이샤 | 글루코키나아제 활성화 물질 |
| US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| AU2008310519B2 (en) * | 2007-10-08 | 2013-05-02 | Advinus Therapeutics Private Limited | Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| US9340506B2 (en) | 2007-10-08 | 2016-05-17 | Advinus Therapeutics Limited | Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| AR070107A1 (es) * | 2008-01-15 | 2010-03-17 | Lilly Co Eli | R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia |
| EP2236498A4 (en) | 2008-01-18 | 2012-02-22 | Astellas Pharma Inc | PHENYLACETAMIDE DERIVATIVE |
| CA2722733C (en) | 2008-04-28 | 2016-02-23 | Kyorin Pharmaceutical Co., Ltd. | Cyclopentylacrylamide derivative |
| GEP20135783B (en) | 2008-05-16 | 2013-03-11 | Takeda California Inc | Glucokinase activators |
| EP2445908A1 (en) | 2009-06-22 | 2012-05-02 | Cadila Healthcare Limited | Disubstituted benzamide derivatives as glucokinase (gk) activators |
| MX2012001228A (es) | 2009-07-31 | 2012-04-20 | Cadila Healthcare Ltd | Derivados de benzamida sustituidos como activadores de glucocinasa (gk). |
| WO2011080755A1 (en) | 2009-12-29 | 2011-07-07 | Advinus Therapeutics Private Limited | Fused nitrogen heterocyclic compounds, process of preparation and uses thereof |
| WO2011095997A1 (en) | 2010-02-08 | 2011-08-11 | Advinus Therapeutics Private Limited | Benzamide compounds as glucokinase activators and their pharmaceutical application |
| BR112012021231A2 (pt) | 2010-02-26 | 2015-09-08 | Basf Plant Science Co Gmbh | método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto |
| EP2539364A1 (en) | 2010-02-26 | 2013-01-02 | Novo Nordisk A/S | Peptides for treatment of obesity |
| EP2552950A1 (en) | 2010-03-26 | 2013-02-06 | Novo Nordisk A/S | Novel glucagon analogues |
| CA2800498C (en) | 2010-03-31 | 2021-11-16 | The Scripps Research Institute | Reprogramming cells |
| EP2402327B1 (en) | 2010-06-29 | 2018-03-07 | Impetis Biosciences Ltd. | Acetamide compounds as glucokinase activators, their process and medicinal applications |
| US20140031278A1 (en) | 2011-03-28 | 2014-01-30 | Novo Nordisk A/S | Novel Glucagon Analogues |
| AR088161A1 (es) | 2011-09-23 | 2014-05-14 | Novo Nordisk As | Analogos de glucagon |
| MX362275B (es) | 2013-04-18 | 2019-01-10 | Novo Nordisk As | Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico. |
| CN106536547A (zh) | 2014-06-04 | 2017-03-22 | 诺和诺德股份有限公司 | 用于医疗用途的glp‑1/胰高血糖素受体共激动剂 |
| EP3596107A1 (en) | 2017-03-15 | 2020-01-22 | Novo Nordisk A/S | Bicyclic compounds capable of binding to melanocortin 4 receptor |
| US20210221867A1 (en) | 2018-05-15 | 2021-07-22 | Novo Nordisk A/S | Compounds Capable of Binding to Melanocortin 4 Receptor |
| EP4487909A3 (en) | 2018-06-12 | 2025-03-19 | vTv Therapeutics LLC | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| WO2020053414A1 (en) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Bicyclic compounds capable of acting as melanocortin 4 receptor agonists |
| WO2021167840A1 (en) | 2020-02-18 | 2021-08-26 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| MX2022015525A (es) | 2020-06-08 | 2023-03-23 | Vtv Therapeutics Llc | Sales o co-cristales del acido {2-[3-ciclohexil-3-(trans-4-propoxi ciclohexil)ureido]tiazol-5-ilsulfanil}acetico y usos de los mismos. |
| CN117209448A (zh) * | 2023-09-13 | 2023-12-12 | 济宁医学院 | 含(苯并)噻唑硫代/硒代乙酰胺及其衍生物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3776917A (en) * | 1972-06-05 | 1973-12-04 | Schering Corp | 2-amino-6-phenalkyl-aminopyridines and derivatives thereof |
| JPS5564592A (en) * | 1978-11-10 | 1980-05-15 | Teijin Ltd | Thiazolo 3, 2-a pyrimidine derivative, its preparation, and drug comprising it |
| JPS62153273A (ja) * | 1985-12-26 | 1987-07-08 | Tokuyama Soda Co Ltd | ピラゾ−ル化合物 |
| BR0009486B1 (pt) * | 1999-03-29 | 2011-03-09 | composto que compreende uma amida, composição farmacêutica que compreende esse composto, seu uso e processo para a preparação do mesmo. |
-
2001
- 2001-07-11 DE DE60111534T patent/DE60111534T2/de not_active Expired - Lifetime
- 2001-07-11 PT PT01967150T patent/PT1305301E/pt unknown
- 2001-07-11 ES ES01967150T patent/ES2243547T3/es not_active Expired - Lifetime
- 2001-07-11 CA CA002416229A patent/CA2416229C/en not_active Expired - Fee Related
- 2001-07-11 AU AU8760001A patent/AU8760001A/xx active Pending
- 2001-07-11 EP EP01967150A patent/EP1305301B1/en not_active Expired - Lifetime
- 2001-07-11 DK DK01967150T patent/DK1305301T3/da active
- 2001-07-11 KR KR1020037000822A patent/KR100556323B1/ko not_active Expired - Fee Related
- 2001-07-11 AU AU2001287600A patent/AU2001287600B2/en not_active Ceased
- 2001-07-11 AT AT01967150T patent/ATE297907T1/de not_active IP Right Cessation
- 2001-07-11 BR BR0112658-0A patent/BR0112658A/pt not_active IP Right Cessation
- 2001-07-11 CN CNB01813050XA patent/CN1184214C/zh not_active Expired - Fee Related
- 2001-07-11 JP JP2002514115A patent/JP4138478B2/ja not_active Expired - Fee Related
- 2001-07-11 MX MXPA03000365A patent/MXPA03000365A/es active IP Right Grant
- 2001-07-11 WO PCT/EP2001/007994 patent/WO2002008209A1/en not_active Ceased
- 2001-07-13 US US09/905,152 patent/US6486184B2/en not_active Expired - Fee Related
- 2001-07-18 PA PA20018522701A patent/PA8522701A1/es unknown
- 2001-07-18 AR ARP010103437A patent/AR032626A1/es active IP Right Grant
- 2001-07-19 UY UY26850A patent/UY26850A1/es not_active Application Discontinuation
- 2001-07-19 PE PE2001000731A patent/PE20020335A1/es not_active Application Discontinuation
- 2001-07-20 GT GT200100146A patent/GT200100146A/es unknown
-
2002
- 2002-06-25 US US10/179,717 patent/US6608218B2/en not_active Expired - Fee Related
-
2003
- 2003-01-07 ZA ZA200300173A patent/ZA200300173B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004504388A5 (enExample) | ||
| JP2004521095A5 (enExample) | ||
| RU2002118339A (ru) | Транс-олефиновые активаторы глюкокиназы | |
| CA2430579A1 (en) | Isoindolin-1-one glucokinase activators | |
| CA2565813A1 (en) | Substituted methyl aryl or heteroaryl amide compounds | |
| JP2004506632A5 (enExample) | ||
| CA2407428A1 (en) | Hydantoin-containing glucokinase activators | |
| JP2005501120A5 (enExample) | ||
| RU98100866A (ru) | Ароматические соединения и содержащие их фармацевтические композиции | |
| WO1992009279A1 (fr) | Derive de 2-arylthiazole et composition pharmaceutique contenant ce derive | |
| CA2509086A1 (en) | Substituted arylcyclopropylacetamides as glucokinase activators | |
| JP2004502670A5 (enExample) | ||
| CA2482346A1 (en) | Substituted phenylacetamides and their use as glucokinase activators | |
| WO2005044192A3 (en) | Triazole compounds and uses related thereto | |
| CA2413313A1 (en) | Antitumor effect potentiators | |
| CA2535749A1 (en) | Ppar activating compound and pharmaceutical composition containing same | |
| WO2011035900A1 (en) | New thiadiazole derivatives | |
| CA2683738A1 (en) | Indanone derivatives that inhibit prolyl hydroxylase | |
| CA2453747A1 (en) | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use | |
| JP2005526696A5 (enExample) | ||
| CA2461916A1 (en) | Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis | |
| JP2010506919A5 (enExample) | ||
| JP2023062064A5 (enExample) | ||
| RU2004129285A (ru) | Производные тиазола в качестве антагонистов рецептора npy | |
| JP2005515976A5 (enExample) |